Rocket Pharmaceuticals Announces Dr. Patel’s Departure Agreement

An announcement from Rocket Pharmaceuticals ( (RCKT) ) is now available.

On September 11, 2025, Rocket Pharmaceuticals, Inc. formalized the departure of Dr. Kinnari Patel through a Separation and Release Agreement, following her decision to join RTW Investments LP as a venture partner. The agreement entitles Dr. Patel to her current salary and benefits until December 31, 2025, a lump sum severance payment, and a healthcare allowance. Additionally, Dr. Patel entered into a Consulting Agreement with Rocket Pharmaceuticals, effective after the revocation period of the Release of Claims, to provide consulting services until December 31, 2026, while retaining her stock options and units.

The most recent analyst rating on (RCKT) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Rocket Pharmaceuticals stock, see the RCKT Stock Forecast page.

Spark’s Take on RCKT Stock

According to Spark, TipRanks’ AI Analyst, RCKT is a Underperform.

Rocket Pharmaceuticals’ overall score reflects its position as a biotechnology firm in the development phase, with significant financial risks due to its lack of revenue and reliance on external financing. Technical indicators suggest potential volatility, while the negative P/E ratio highlights current valuation challenges. The company’s strong equity position is a positive factor, but ongoing cash burn remains a critical concern.

To see Spark’s full report on RCKT stock, click here.

More about Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc. operates in the biotechnology industry, focusing on developing gene therapies for rare and devastating diseases. The company is dedicated to advancing its pipeline of innovative treatments to address significant unmet medical needs.

Average Trading Volume: 4,077,935

Technical Sentiment Signal: Sell

Current Market Cap: $347.5M

Learn more about RCKT stock on TipRanks’ Stock Analysis page.